CellCept (Mycophenolate Mofetil) for Thyroid Eye Disease

Overview 
CellCept is an immunosuppressant drug approved by the U.S. Food and Drug Administration (FDA) for the prevention of organ rejection after kidney, heart, or liver transplants. While not FDA-approved for thyroid eye disease (TED), CellCept may be prescribed off-label for TED if the usual treatments are not working. CellCept is also known by its drug name, mycophenolate mofetil.

Mycophenolate mofetil works by inhibiting the proliferation of B and T lymphocytes, types of white blood cells, to reduce the inflammation and autoimmune reactions that contribute to TED.

How do I take it?
CellCept is available as capsules, tablets, an oral suspension, and an intravenous formulation. Your doctor will advise you on how best to take it and in what dose. It is crucial to take this medication exactly as prescribed by a health care provider.

Side effects
Common side effects of CellCept include diarrhea, a decrease in the number of white blood cells, vomiting, and a higher risk of opportunistic infections.

Rare but serious side effects may include increased risk of lymphoma and other malignancies, particularly skin cancers. It also increases the risk of severe, potentially fatal infections. CellCept can cause fetal harm to pregnant people.

For more information about this treatment, visit:

CellCept (Mycophenolate Mofetil) — DailyMed

CellCept (Mycophenolate Mofetil) — Genentech